D. Gibson

发表

What do we know about the reduction of Pt(IV) pro-drugs?

E. Wexselblatt, D. Gibson, 2012, Journal of inorganic biochemistry.

The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human.

N. Wood, D. Smith, D. Walker, 2003, Drug metabolism and disposition: the biological fate of chemicals.

Nuclear localization signal-targeted poly(ethylene glycol) conjugates as potential carriers and nuclear localizing agents for carboplatin analogues.

A. Gabizon, M. Fuertes, J. Pérez, 2004, Bioconjugate chemistry.

A Lipophilic Pt(IV) Oxaliplatin Derivative Enhances Antitumor Activity.

S. Benita, D. Gibson, T. Nassar, 2016, Journal of medicinal chemistry.

Molecular structure of the complex formed between the anticancer drug cisplatin and d(pGpG): C222(1) crystal form.

A. Wang, S. Lippard, D. Gibson, 1990, Journal of biomolecular structure & dynamics.

Synthesis and antitumor activity of quinonoid derivatives of cannabinoids.

D. Gibson, R. Mechoulam, P. Sándor, 2004, Journal of medicinal chemistry.

Peculiar mechanistic and structural features of the carboplatin–cytochrome c system revealed by ESI-MS analysis

A. Casini, G. Mastrobuoni, L. Messori, 2008, JBIC Journal of Biological Inorganic Chemistry.

Interactions of cisplatin and transplatin with proteins. Comparison of binding kinetics, binding sites and reactivity of the Pt-protein adducts of cisplatin and transplatin towards biological nucleophiles.

D. Gibson, Y. Najajreh, T. Peleg-Shulman, 2002, Journal of inorganic biochemistry.

Folate-targeted PEG as a potential carrier for carboplatin analogs. Synthesis and in vitro studies.

A. Gabizon, D. Gibson, O. Aronov, 2003, Bioconjugate chemistry.

In vivo biodistribution of platinum-based drugs encapsulated into multi-walled carbon nanotubes.

G. Pastorin, A. Bianco, S. Ramaprabhu, 2014, Nanomedicine : nanotechnology, biology, and medicine.

Antitumor platinum(IV) derivatives of oxaliplatin with axial valproato ligands.

V. Brabec, J. Kašpárková, D. Gibson, 2014, Journal of inorganic biochemistry.

The timing of caffeic acid treatment with cisplatin determines sensitization or resistance of ovarian carcinoma cell lines

D. Gibson, R. Kohen, R. Sirota, 2016, Redox biology.

A Multi‐action and Multi‐target Ru II –Pt IV Conjugate Combining Cancer‐Activated Chemotherapy and Photodynamic Therapy to Overcome Drug Resistant Cancers

G. Gasser, D. Gibson, Thirumal Yempala, 2020, Angewandte Chemie.

A Multiaction and Multitarget Ru(II)-Pt(IV) Conjugate Combining Cancer Activated Chemotherapy and Photodynamic Therapy to Overcome Drug Resistant Cancers.

G. Gasser, D. Gibson, Thirumal Yempala, 2020, Angewandte Chemie.

Synthesis and Cytotoxicity of Water-Soluble Dual- and Triple-Action Satraplatin Derivatives: Replacement of Equatorial Chlorides of Satraplatin by Acetates.

D. Gibson, P. Heffeter, C. Kowol, 2019, Inorganic chemistry.

Triple action Pt(iv) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c8sc00428e

V. Gandin, D. Gibson, Emanuele Petruzzella, 2018, Chemical science.

On the stability of Pt(IV) pro-drugs with haloacetato ligands in the axial positions.

E. Yavin, E. Wexselblatt, D. Gibson, 2015, Chemistry.

Pt(IV) analogs of oxaliplatin that do not follow the expected correlation between electrochemical reduction potential and rate of reduction by ascorbate.

T. Hambley, E. Wexselblatt, D. Gibson, 2012, Chemical communications.

Platinum(IV) prodrugs with haloacetato ligands in the axial positions can undergo hydrolysis under biologically relevant conditions.

E. Yavin, E. Wexselblatt, D. Gibson, 2013, Angewandte Chemie.

New reduction pathways for ctc-[PtCl2(CH3CO2)2(NH3)(Am)] anticancer prodrugs.

K. Takrouri, D. Gibson, A. Mijovilovich, 2010, Chemical communications.

Soybean oil emulsion administration during parenteral nutrition in the preterm infant: effect on essential fatty acid, lipid, and glucose metabolism.

R. Cooke, D. Gibson, Y. Yeh, 1987, The Journal of pediatrics.

The mechanism of action of platinum anticancer agents--what do we really know about it?

D. Gibson, 2009, Dalton transactions.

Is glutathione the major cellular target of cisplatin? A study of the interactions of cisplatin with cancer cell extracts.

D. Gibson, S. Sturup, Yonit Kasherman, 2009, Journal of medicinal chemistry.

Trans labilization of am(m)ine ligands from platinum(II) complexes by cancer cell extracts

D. Gibson, S. Sturup, Yonit Kasherman, 2009, JBIC Journal of Biological Inorganic Chemistry.

DNA interactions of new cytotoxic tetrafunctional dinuclear platinum complex trans,trans-[{PtCl2(NH3)}2(piperazine)].

V. Brabec, J. Kašpárková, O. Novakova, 2007, Biochemical pharmacology.

Mass spectrometric studies of the formation and reactivity of trans-[PtCl2(Am)(piperidinopiperidine)] x HCl complexes with ubiquitin.

D. Gibson, L. Balter, 2005, Rapid communications in mass spectrometry : RCM.

Novel soluble cationic trans-diaminedichloroplatinum(II) complexes that are active against cisplatin resistant ovarian cancer cell lines.

D. Gibson, C. Navarro-Ranninger, Y. Najajreh, 2002, Journal of medicinal chemistry.

Novel apoptosis-inducing trans-platinum piperidine derivatives: synthesis and biological characterization.

Y. Barenholz, D. Gibson, Y. Najajreh, 2002, Journal of medicinal chemistry.

Oxidation of cis-diamminediacetato Pt(II) with hydrogen peroxide can give rise to two isomeric Pt(IV) products.

D. Gibson, H. Kostrhunova, M. Ishan, 2020, Chemistry.

Multiaction Pt(IV) Carbamate Complexes Can Codeliver Pt(II) Drugs and Amine Containing Bioactive Molecules.

D. Gibson, A. Sarkar, C. Schmidt, 2020, Inorganic chemistry.

Expanding the Arsenal of PtIV Anticancer Agents; Multi-action PtIV Anticancer Agents with Bioactive Ligands Possessing Hydroxyl Functional Group.

V. Gandin, D. Gibson, Thirumal Yempala, 2019, Angewandte Chemie.

Expanding the Arsenal of Pt IV Anticancer Agents: Multi‐action Pt IV Anticancer Agents with Bioactive Ligands Possessing a Hydroxy Functional Group

V. Gandin, D. Gibson, Thirumal Yempala, 2019, Angewandte Chemie.

Probing the Interactions of Cytotoxic [Pt(1S,2S‐DACH)(5,6‐dimethyl‐1,10‐phenanthroline)] and Its PtIV Derivatives with Human Serum

Benjamin W. J. Harper, J. Aldrich-Wright, D. Gibson, 2017, ChemMedChem.

Different features of the DNA binding mode of antitumor cis-amminedichlorido(cyclohexylamine)platinum(II) (JM118) and cisplatin in vitro.

V. Brabec, J. Kašpárková, T. Suchánková, 2010, Chemical research in toxicology.

New insights into the molecular and epigenetic effects of antitumor Pt(IV)-valproic acid conjugates in human ovarian cancer cells.

V. Brabec, J. Kašpárková, D. Gibson, 2015, Biochemical pharmacology.

A new bridging ligand, the hydrogen oxide ion (H3O2-)

D. Gibson, A. Bino, 1981 .

Cellular interactions of platinum drugs

E. Yavin, E. Wexselblatt, D. Gibson, 2012 .

The cytosolic pathway of l-malic acid synthesis in Saccharomyces cerevisiae: the role of fumarase

O. Pines, D. Gibson, S. Even-Ram, 1996, Applied Microbiology and Biotechnology.

Pt(iv) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c5sc04205d

V. Brabec, V. Gandin, E. Wexselblatt, 2016, Chemical science.

Activation of trans geometry in bifunctional mononuclear platinum complexes by a non-bulky methylamine ligand.

V. Brabec, J. Kašpárková, O. Novakova, 2013, Journal of inorganic biochemistry.

Anthraquinone intercalators as carrier molecules for second-generation platinum anticancer drugs

J. Katzhendler, D. Gibson, I. Ringel, 1997 .

Structure and Reactivity of 2-Hydroxyiminobenzyl-2-oxo-4,4,5,5-tetramethyl[1,3,2]dioxaphospholanes

A. Goldblum, D. Gibson, E. Breuer, 1989 .

The gas-phase chemistry of C4H4+−

D. Gibson, I. Dotan, K. Levsen, 1981 .

Structure of the gas-phase ion C6H5+

D. Gibson, K. Levsen, C. Lifshitz, 1980 .

Evaluation of the N-phthaloyl moiety as protecting group in aminoacylphosphonic derivatives

M. Safadi, M. Chorev, D. Gibson, 1991 .

Water soluble cationic trans-platinum complexes which induce programmed cell death in the protozoan parasite Leishmania infantum.

M. Fuertes, C. Alonso, D. Gibson, 2005, Journal of inorganic biochemistry.

A MOLECULE CONTAINING THE OWOWO UNIT. SYNTHESIS, STRUCTURE AND SPECTROSCOPY OF HEXANEOPENTYLDITUNGSTEN TRIOXIDE

S. Lippard, R. Schrock, D. Gibson, 1985 .

DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines.

V. Brabec, J. Kašpárková, D. Gibson, 2003, Biochemistry.

Interactions of platinum complexes containing cationic, bicyclic, nonplanar piperidinopiperidine ligands with biological nucleophiles.

Y. Barenholz, V. Brabec, J. Kašpárková, 2006, Journal of medicinal chemistry.

The trans labilization of cis-[PtCl2(13CH3NH2)2] by glutathione can be monitored at physiological pH by [1H,13C] HSQC NMR

D. Gibson, Inna Freikman, D. Kowarski, 2006, JBIC Journal of Biological Inorganic Chemistry.

Novel amino acid derivatives. Preparation and properties of aminoacylphosphonates and amino hydroxyimini phosphonates

M. Safadi, M. Chorev, D. Gibson, 1990 .

Alkyne-bridged dicopper(I) complexes of the tropocoronand macrocycles

Ian D. Williams, S. Lippard, D. Gibson, 1987 .

Dicopper(I) tropocoronands: synthesis, X-ray crystal structure, and spectral properties of neutral binuclear copper(I) complexes bridged by symmetrically substituted alkynes

Ian D. Williams, S. Lippard, D. Gibson, 1985 .

Preparation, characterization and antileukemic properties of diaminemalonatoplatinum(II) complexes tethered to ferrocene

D. Gibson, A. Ramu, J. Blum, 1992 .

A Quadruple-Action Platinum(IV) Prodrug with Anticancer Activity Against KRAS Mutated Cancer Cell Lines.

V. Gandin, J. Aldrich-Wright, D. Gibson, 2017, Angewandte Chemie.

Stereoselectivity in fragmentation and rearrangement of α-hydroxyimino-phosphinates and -phosphonates. A synthetic approach to acylphosphon- and phosphor-amidates. Crystal structures of methyl (E)-α-hydroxyimino-benzylphenylphosphinate and methyl benzoylphenylphosphonamidate

M. Safadi, M. Chorev, D. Gibson, 1990 .

The effect of cis-platin analogues derived from aminoalkylaminoanthraquinones on DNA cleavage: an electron microscopy study

J. Katzhendler, D. Gibson, I. Ringel, 1988 .

Preparation, characterization, and antitumor properties of cis-PtCl2 complexes linked to anthraquinones through position number 2.

N. Mansur, D. Gibson, K. Gean, 1995, Journal of inorganic biochemistry.

Preparation, characterization and the anticancer activity of a novel series of triaminemonochloroplatinum(II) cations linked to anthraquinone intercalators

D. Gibson, I. Ringel, A. Ramu, 1991 .

Metal complexes of .alpha.-hydroxyimino phosphonic acid derivatives. Separation of E and Z isomers by metal chelation and the preparation and characterization of copper bis[(E)-(.alpha.-(hydroxyimino)benzyl)phosphonate]-water

D. Gibson, R. Karaman, 1989 .

Fragmentation of methyl hydrogen α-hydroxyiminophosphonates to monomeric methyl metaphosphate: stereochemistry and mechanism

J. Katzhendler, D. Gibson, E. Breuer, 1989 .

Metal complexes of α-hydroxyiminophosphonic acid derivatives. Preparation and crystal structures of calcium and cadmium complexes of methyl (E)-α-hydroxyiminobenzylphosphonate

D. Gibson, R. Karaman, 1989 .

α-Hydroxyiminophosphonic acids. New types of phosphorylating agents through monomeric metaphosphate

A. Goldblum, D. Gibson, E. Breuer, 1988 .

α-Oxyiminophosphonates: chemical and physical properties. Reactions, theoretical calculations, and X-ray crystal structures of (E) and (Z)-dimethyl α-hydroxyiminobenzylphosphonates

A. Goldblum, B. Potter, D. Gibson, 1988 .

Crystal and molecular structure of cis-[Pt(NH3)2{d(pGpG)}], the principal adduct formed by cis-diamminedichloroplatinum(II) with DNA

S. Lippard, D. Gibson, A. Wang, 1988 .

Acylphosphonamidates and α‐hydroxyiminophosphonamidates. Synthesis of N‐acylphosphordiamidates by Beckmann rearrangement. Crystal structure of (E)‐α‐hydroxyiminobenzyl‐1‐pyrrolidinylphosphinate

D. Gibson, E. Breuer, Z. Tashma, 1996 .

Evaluation of the N‐Phthaloyl Moiety as Protecting Group in Aminoacylphosphonic Derivatives.

M. Safadi, M. Chorev, D. Gibson, 1991 .

The hydrogen oxide bridging ligand (H3O2−). II: Effect of the hydrogen ion concentration

D. Gibson, A. Bino, 1984 .

THE HYDROGEN OXIDE BRIDGING LIGAND (H3O2-). 1. DIMERIZATION AND POLYMERIZATION OF HYDROLYZED TRINUCLEAR METAL CLUSTER IONS

D. Gibson, A. Bino, 1982 .

Oxalato complexes of the trinuclear aquo ion of molybdenum(IV), [Mo3O4]4+

Dan Gibson, F. Albert Cotton, F. Cotton, 1985 .

Cytotoxicity, mutagenicity, cellular uptake, DNA and glutathione interactions of lipophilic trans-platinum complexes tethered to 1-adamantylamine.

V. Brabec, G. Natile, J. Kašpárková, 2008, Journal of inorganic biochemistry.

Facile preparation of mono-, di- and mixed-carboxylato platinum(IV) complexes for versatile anticancer prodrug design.

T. Hambley, E. Wexselblatt, D. Gibson, 2013, Chemistry.

Novel carboplatin analogs containing flexible and potentially intercalating ligands: preparation and X-ray crystal structures of di-2-pyridyl ketone cyclobutanedicarboxylate platinum(II) and of 2,3-bis(2-pyridyl)pyrazine cyclobutane dicarboxylate platinum(II)

D. Gibson, A. Bino, Alba D. Q. Ferreira, 1997 .

Platinum(iv) anticancer prodrugs - hypotheses and facts.

D. Gibson, 2016, Dalton transactions.

Preparation and structural characterization of a novel hexanuclear complex of platinum(II) with 2-aminoethanethiolate

S. Lippard, D. Gibson, 1986 .

X-ray structure of the major adduct of the anticancer drug cisplatin with DNA: cis-[Pt(NH3)2(d(pGpG))].

A. Wang, S. Lippard, D. Gibson, 1985, Science.

Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?

D. Gibson, 2021, Journal of inorganic biochemistry.

Drug–DNA interactions and novel drug design

D. Gibson, 2002, The Pharmacogenomics Journal.

Structure and unique interactions with DNA of a cationic trans-platinum complex with the nonplanar bicyclic piperidinopiperidine ligand.

Y. Barenholz, V. Brabec, J. Kašpárková, 2005, Angewandte Chemie.

Tritungsten(IV) cluster compounds with hydroxo ligands. Preparation and structure of [W3O2(O2CCH3)6(H2O)(OH)2]·16H2O and [W3O2(O2CCH3)6(H2O)(OH)2]·KBr·15H2O

D. Gibson, A. Bino, 1985 .

Trinuclear Mo(IV) cluster ion with a propylidyne cap

D. Gibson, A. Bino, 1982 .

Donor atom preferences in substitution reactions of trans-platinum mononucleobase compounds : Implications for DNA-protein selectivity

N. Farrell, A. Anzellotti, D. Gibson, 2006 .

Epigenetic and antitumor effects of platinum(IV)-octanoato conjugates

V. Brabec, J. Kašpárková, I. Zanellato, 2017, Scientific Reports.

Activation of Trans Geometry in Bifunctional Mononuclear Platinum Complexes by a Piperidine Ligand

V. Brabec, J. Kašpárková, O. Novakova, 2003, Journal of Biological Chemistry.

Ligand effects on the binding of cis- and trans-[PtCl2Am1Am2] to proteins

N. Farrell, D. Gibson, Ofra Moshel, 2002, JBIC Journal of Biological Inorganic Chemistry.

A Subset of New Platinum Antitumor Agents Kills Cells by a Multimodal Mechanism of Action Also Involving Changes in the Organization of the Microtubule Cytoskeleton.

V. Brabec, J. Kašpárková, J. Aldrich-Wright, 2019, Journal of medicinal chemistry.

An Anticancer PtIV Prodrug That Acts by Mechanisms Involving DNA Damage and Different Epigenetic Effects.

V. Brabec, J. Kašpárková, D. Gibson, 2019, Chemistry.

PHARMACOKINETICS AND METABOLISM OF A NEW POTENT ANTIEPILEPTIC DRUG, 2,2,3,3-TETRAMETHYCYCLOPROPANECARBONYLUREA, IN RATS

M. Bialer, D. Gibson, M. Britzi, 2005, Drug Metabolism and Disposition.

Oxoplatin‐Based Pt(IV) Lipoate Complexes and Their Biological Activity

M. Jakupec, B. Keppler, W. Weigand, 2022, Chemistry & biodiversity.

Epigenetic and antitumor effects of platinum(IV)-octanoato conjugates

V. Brabec, J. Kašpárková, I. Zanellato, 2017, Scientific Reports.

Platinum(IV)-Estramustine Multiaction Prodrugs Are Effective Antiproliferative Agents against Prostate Cancer Cells.

V. Brabec, D. Gibson, H. Kostrhunova, 2020, Journal of medicinal chemistry.

Are Pt(IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs?

V. Brabec, V. Gandin, D. Gibson, 2021, Journal of medicinal chemistry.

Multi-action Pt(IV) anticancer agents; do we understand how they work?

D. Gibson, 2019, Journal of inorganic biochemistry.

Studies on cellular accumulation of satraplatin and its major metabolite JM118 and their interactions with glutathione.

V. Brabec, J. Kašpárková, D. Gibson, 2010, Molecular pharmaceutics.

Reduction of cis,trans,cis-[PtCl2(OCOCH3)2(NH3)2] by aqueous extracts of cancer cells.

D. Gibson, A. Nemirovski, Yonit Kasherman, 2007, Journal of medicinal chemistry.

Zygote serine decreased uptake from the fertilization medium is associated with implantation and pregnancy

D. Gibson, E. Aizenman, Y. Shufaro, 2014, Journal of Assisted Reproduction and Genetics.

The role of the catecholic and the electrophilic moieties of caffeic acid in Nrf2/Keap1 pathway activation in ovarian carcinoma cell lines

D. Gibson, R. Kohen, R. Sirota, 2014, Redox biology.

Dual‐Targeting Dual‐Action Platinum(IV) Platform for Enhanced Anticancer Activity and Reduced Nephrotoxicity

G. Pastorin, E. Chow, L. Hooi, 2019, Angewandte Chemie.

Influence of the Fatty Acid Metabolism on the Mode of Action of a Cisplatin(IV) Complex with Phenylbutyrate as Axial Ligands

C. Pirker, W. Berger, M. Grusch, 2023, Pharmaceutics.

The induction of lysis in lysogenic strains of Escherichia coli by a new antitumor transplatin derivative and its DNA interactions.

V. Brabec, J. Kašpárková, O. Novakova, 2015, Dalton transactions.

Structural characterization and DNA interactions of new cytotoxic transplatin analogues containing one planar and one nonplanar heterocyclic amine ligand

V. Brabec, J. Kašpárková, D. Gibson, 2005, JBIC Journal of Biological Inorganic Chemistry.

Mass spectrometry of biomolecules

C. Costello, D. Gibson, 2000 .

Ternary Pt(II)-amino acid-nucleotide complexes: kinetics of formation

H. Berman, D. Gibson, G. Arvanitis, 1994 .

Dual-Targeting Dual-Action Platinum(IV) Platform for Enhanced Anticancer Activity and Reduced Nephrotoxicity.

G. Pastorin, E. Chow, L. Hooi, 2019, Angewandte Chemie.

Potentiation of mitochondrial dysfunction in tumor cells by conjugates of metabolic modulator dichloroacetate with a Pt(IV) derivative of oxaliplatin.

V. Brabec, J. Kašpárková, D. Gibson, 2016, Journal of inorganic biochemistry.

A Mass Spectral Study of the Binding of the Anticancer Drug Cisplatin to Ubiquitin

C. Costello, D. Gibson, 1999 .

Pt(IV) Anticancer Prodrugs – A Tale of Mice and Men

D. Gibson, 2021, ChemMedChem.

trans-Platinum(iv) pro-drugs that exhibit unusual resistance to reduction by endogenous reductants and blood serum but are rapidly activated inside cells: 1H NMR and XANES spectroscopy study.

T. Hambley, D. Gibson, P. Kappen, 2020, Dalton transactions.

Synthesis, characterization and in vitro and in vivo anticancer activity of Pt(iv) derivatives of [Pt(1S,2S-DACH)(5,6-dimethyl-1,10-phenanthroline)].

V. Gandin, Benjamin W. J. Harper, J. Aldrich-Wright, 2017, Dalton transactions.

Preparation, Characterization, and Anticancer Activity of a Series of cis-PtCl2 Complexes Linked to Anthraquinone Intercalators.

J. Katzhendler, D. Gibson, I. Ringel, 1991 .

A new, convenient, and efficient route to dimolybdenum(II) compounds from molybdenum oxide (MoO3)

D. Gibson, A. Bino, 1980 .

Synthesis and NMR structural studies of the adduct of trans-diamminedichloroplatinum(II) with the DNA fragment d(GpCpG)

S. Lippard, D. Gibson, 1987 .

Cationic nonsymmetric transplatinum complexes with piperidinopiperidine ligands. Preparation, characterization, in vitro cytotoxicity, in vivo toxicity, and anticancer efficacy studies.

Y. Barenholz, V. Brabec, J. Kašpárková, 2006, Journal of medicinal chemistry.

Pt(iv) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c5sc04205d

V. Brabec, V. Gandin, E. Wexselblatt, 2016, Chemical science.

Dibenzofuran annulated 1-azepines: Synthesis and cytotoxicity

D. Gibson, B. Cassels, Thirumal Yempala, 2020 .

Isolation and structure of a brain constituent that binds to the cannabinoid receptor.

D. Gibson, R. Mechoulam, W. Devane, 1992, Science.

Ligand effects on the binding of cis- and trans-[PtCl(2)Am(1)Am(2)] to proteins.

N. Farrell, D. Gibson, Ofra Moshel, 2003, Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry.

Cytotoxicity, mutagenicity, cellular uptake, DNA and glutathione interactions of lipophilic trans-platinum complexes tethered to 1-adamantylamine.

V. Brabec, G. Natile, J. Kašpárková, 2008, Journal of inorganic biochemistry.

Toxicity in tumor cells, DNA binding mode, and resistance to decomposition by sulfur nucleophiles of new dinuclear bifunctional trans-PtII complexes containing long alkane linkers

V. Brabec, J. Kašpárková, O. Novakova, 2012 .

Effects of a piperidine ligand on DNA modification by antitumor cisplatin analogues.

V. Brabec, J. Kašpárková, O. Novakova, 2003, Chemical research in toxicology.

Preparation, characterization, and anticancer activity of a series of cis-PtCl2 complexes linked to anthraquinone intercalators.

D. Gibson, K. Gean, R. Ben-Shoshan, 1991, Journal of Medicinal Chemistry.

Is glutathione the major cellular target of cisplatin? A study of the interactions of cisplatin with cancer cell extracts.

D. Gibson, S. Sturup, Yonit Kasherman, 2009, Journal of medicinal chemistry.